Researchers find promise in Gem/Doce as an alternative therapy for patients with NMIBC recurrence after BCG induction.
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Drs. Packiam and Yerram conclude with an AI-powered pathology tool designed to predict response to BCG in NMIBC.
Drs. Packiam and Yerram shift focus to SunRISe-1 Cohort 4, which examined BCG-unresponsive papillary disease.
Drs. Packiam and Yerram contextualize recent data from the CREST trial, which evaluated sasanlimab with BCG for HR NMIBC.
Drs. Packiam and Yerram focus on how agents like gem/doce, pembro, nadofaragene, cretostimogene, and TAR-200 are used.
Drs. Packiam and Yerram discuss TAR-200 and the ongoing SunRISe-3 trial exploring its effectiveness amid BCG shortages.
Drs. Packiam and Yerram discuss the emergence of gem/doce as a promising alternative to BCG.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
Advertisement
Section Editor
Sia Daneshmand, MDEditor | Professor of Urology and Medicine (Oncology) at the University of Southern California
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.